Mayo Clinic News Network

News Resources

Items tagged as "Edith Perez"

Immune Function Marker Does Not Predict Benefit of Trastuzumab in HER-2+ Breast Cancer Patients, Study Finds

JACKSONVILLE, Fla. — A marker of immune function that predicts for better outcomes in patients treated with chemotherapy for triple negative breast cancer is also linked to improved prognosis in patients treated with chemotherapy for HER2-positive breast cancer. But that marker — the quantity of tumor-infiltrating lymphocytes (S-TILs) in a [...]

Created by Paul Scotti

Perez: Immune Function Marker - Edited PKG (4:19)

Dr. Edith Perez, deputy director at large, Mayo Clinic Cancer Center, and director of the Breast Cancer Translational Genomics Program at Mayo Clinic in Florida, discusses new study findings: A marker of immune function that predicts for better outcomes in patients treated with chemotherapy for triple negative breast cancer is [...]

Created by Jason Pratt

Perez: Immune Function Marker - Implications for Practice (:53)

Dr. Edith Perez, deputy director at large, Mayo Clinic Cancer Center, and director of the Breast Cancer Translational Genomics Program at Mayo Clinic in Florida, discusses new study findings: A marker of immune function that predicts for better outcomes in patients treated with chemotherapy for triple negative breast cancer is [...]

Created by Jason Pratt

Perez: Immune Function Marker - Study Results (1:24)

Dr. Edith Perez, deputy director at large, Mayo Clinic Cancer Center, and director of the Breast Cancer Translational Genomics Program at Mayo Clinic in Florida, discusses new study findings: A marker of immune function that predicts for better outcomes in patients treated with chemotherapy for triple negative breast cancer is [...]

Created by Jason Pratt

Perez: Immune Function Marker - Current Standard (:27)

Dr. Edith Perez, deputy director at large, Mayo Clinic Cancer Center, and director of the Breast Cancer Translational Genomics Program at Mayo Clinic in Florida, discusses new study findings: A marker of immune function that predicts for better outcomes in patients treated with chemotherapy for triple negative breast cancer is [...]

Created by Jason Pratt

Perez: Immune Function Marker - Evaluation (:20)

Dr. Edith Perez, deputy director at large, Mayo Clinic Cancer Center, and director of the Breast Cancer Translational Genomics Program at Mayo Clinic in Florida, discusses new study findings: A marker of immune function that predicts for better outcomes in patients treated with chemotherapy for triple negative breast cancer is [...]

Created by Jason Pratt

Perez: Immune Function Marker - Background (1:00)

Dr. Edith Perez, deputy director at large, Mayo Clinic Cancer Center, and director of the Breast Cancer Translational Genomics Program at Mayo Clinic in Florida, discusses new study findings: A marker of immune function that predicts for better outcomes in patients treated with chemotherapy for triple negative breast cancer is [...]

Created by Jason Pratt

Em mais de oito anos de tratamento do câncer de mama HER2-positivo em estágio inicial, o trastuzumabe continua a apresentar benefícios para sobrevida das pacientes

Em mais de oito anos de tratamento do câncer de mama HER2-positivo em estágio inicial, o trastuzumabe continua a apresentar benefícios para sobrevida das pacientes

JACKSONVILLE, Flórida, 21 de outubro de 2014 — Depois de acompanhar pacientes de câncer de mama por mais de oito anos, em média, pesquisadores dizem que o acréscimo do trastuzumabe (Herceptin) à quimioterapia melhorou significativamente a sobrevida das pacientes, sem a doença, de mulheres com câncer de mama HER2-positivo em [...]

Created by Kevin Punsky

Load More